ACH at a glance
ACCENDRA HEALTH INC/VA/ (ACH, SEC CIK 75252) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 28, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ACCENDRA HEALTH INC/VA/ (ACH) reported revenue of $2.8 billion (down 74.2% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$14.31.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.8B
- −74.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- Latest 8-K
- Sep 28, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $613.2M, down 10.1% YoY from $681.9M, driven by commercial payor contract termination
- Cost margin 57.0% vs 52.4% YoY; SG&A margin 39.7% vs 39.3%
- Best segment Urology, revenue $31.3M, up 9.1%; worst Other, $47.7M, down 34.1%
- Cash $7.7M vs $282.0M at December 31; six-month operating cash flow $(76.1)M
- Free cash flow $(25.1)M vs $15.2M; $43.8M patient-service equipment capital expenditures
Risk Factors
- No material changes to 10-K risk factors through June 30, 2026
- Debt risk: New 9.000% senior secured notes due 2032
- Debt risk: New 9.750% senior secured notes due 2033
- Liquidity risk: $100 million repurchase authorization, with $89.860 million remaining
AI summary of the ACH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Gardner-Smith assumes President and CEO role October 5, 2026
- Pesicka remains CEO until transition, then retires from the Board
Item 7.01: Regulation FD Disclosure
- Filing contains only signature and cover-page XBRL information
- No substantive Regulation FD disclosure or investor-relevant operating update included
Item 8.01: Other Events
- Scott Lloyd appointed Chief Commercial Officer effective October 5, 2026
- New role consolidates commercial strategy, sales, and provider and payor partnerships
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Kenneth Gardner-Smith named CEO, succeeding retiring Edward Pesicka in early Q4 2026
- Pesicka remains advisor during transition, then retires from the Board
Item EX-99.1: Item EX-99.1
- Kenneth Gardner-Smith to become President and CEO early Q4 2026, succeeding retiring CEO Edward Pesicka
- Gardner-Smith’s board tenure since March 2022 supports continuity while bringing healthcare operating leadership from Veritas and DaVita
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD disclaimer limiting Securities Exchange Act Section 18 liability
- Exhibit content not incorporated into Securities Act filings unless expressly referenced
Item EX-99.1: Item EX-99.1
- ATM equity program canceled, eliminating planned opportunistic issuance for debt reduction and avoiding potential shareholder dilution
- $300 million revolver undrawn at second-quarter end, supporting management’s stated liquidity confidence
AI summaries of ACH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACH
Don't miss the next ACH filing
- Alerts as it files. A push when ACH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACH, by share count.
- Ask anything. An AI agent that reads every ACH filing and answers with sources.
ACH alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Gardner-Smith Kenneth | A | Oct 5, 2026 | 283,554 | - |
| Leon Jonathan A | F | Sep 23, 2026 | 4,265 | $0.85 |
| Galloway Heath H | F | May 18, 2026 | 1,822 | $2.91 |
| Galloway Heath H | F | May 15, 2026 | 966 | $3.04 |
| Gardner-Smith Kenneth | A | May 14, 2026 | 31,191 | - |
| Pesicka Edward A | F | Mar 20, 2026 | 58,945 | $2.03 |
| Galloway Heath H | F | Mar 20, 2026 | 9,347 | $2.03 |
| Leon Jonathan A | F | Mar 20, 2026 | 11,286 | $2.03 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $10.7B | $2.8B |
| Gross Profit | - | $2.2B | - |
| Operating Income | - | -$207.8M | $27.5M |
| Net Income | - | -$362.7M | -$1.1B |
| Gross Margin | - | 20.7% | - |
| Op. Margin | - | -1.9% | 1.0% |
| Net Margin | - | -3.4% | -39.8% |
| Balance Sheet | |||
| Total Assets | $5.1B | $4.7B | $2.5B |
| Equity | $924.2M | $565.2M | -$461.0M |
| ROE | - | -64.2% | 238.8% |
| Per Share | |||
| EPS | - | $-4.73 | $-14.31 |
| Cash Flow | |||
| Operating CF | - | $161.5M | -$101.8M |
| CapEx | $190.9M | $210.9M | $191.0M |
Source: XBRL data in ACCENDRA HEALTH INC/VA/ (ACH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
ACH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 6, 2026 | - | - | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 24, 2026 | - | - | - |
| 8-K | Sep 17, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jun 25, 2026 | - | Analysis | - |
| 8-K | Jun 15, 2026 | - | Analysis | - |
| 8-K | May 22, 2026 | - | Analysis | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 19, 2026 | - | - | |
| 4 | May 18, 2026 | - | - | |
| 8-K | May 15, 2026 | - | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 10-Q | May 11, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| SC 13G | Mar 30, 2026 | - | - | |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 24, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
Related Health Care companies
- HSIC · Henry ScheinWholesale-Medical, Dental & Hospital Equipment & Supplies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
ACH SEC filings: frequently asked questions
What was ACH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ACCENDRA HEALTH INC/VA/ (ACH) reported revenue of $2.8 billion (down 74.2% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$14.31. The figures come from the XBRL data in the 10-K.
What did ACH report in its latest 8-K?
ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K on September 28, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Gardner-Smith assumes President and CEO role October 5, 2026.
What are the latest ACH SEC filings?
ACCENDRA HEALTH INC/VA/ (ACH) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on September 28, 2026 and a Form 4 insider filing on October 6, 2026.
What is ACH's SEC CIK number?
ACCENDRA HEALTH INC/VA/ (ACH)'s SEC Central Index Key (CIK) is 75252. EDGAR lists every ACH filing under that number.
Ask anything about ACH
The research agent reads ACH's filings, financials, insider trades and 13F holders, then answers with sources.